Dargenio M, Buquicchio C, Pastore D, Aprile L, Ciuffreda L, Greco G, Delia M, Federico V, Fina M P, Seripa D, Matera R, Tarantini G, Maggi A, Melillo L, Pavone V, Musto P, Specchia G, Renzo N Di
Hematology and Stem Cell Transplant Unit, "Vito Fazzi" Hospital, Lecce, Italy.
Hematology Unit, Dimiccoli Hospital, Barletta, Italy.
Leuk Res Rep. 2025 Jun 28;24:100525. doi: 10.1016/j.lrr.2025.100525. eCollection 2025.
Gemtuzumab Ozogamicin, a monoclonal antibody targeting CD33, linked to calicheamicin, is approved in combination with "3 + 7″ for the treatment of patients with de novo CD33 positive AML. The aim of study was to evaluate the outcome of patients receiving 3 + 7 plus GO as front-line therapy outside clinical trials. Between March 2020 and February 2023, 34 consecutive fit CD33+ AML patients, median age 54.5 years (range, 25-75) were treated. This study confirms the efficacy and toxicity data reported in clinical trials, highlighting the feasibility of GO based chemotherapy also in patients older than 60 years and as a bridge to allo-HSCT.
吉妥珠单抗奥唑米星是一种靶向CD33的单克隆抗体，与卡奇霉素连接，被批准与“3 + 7”方案联合用于治疗初治CD33阳性急性髓系白血病（AML）患者。本研究的目的是评估在临床试验之外接受“3 + 7”方案加吉妥珠单抗奥唑米星作为一线治疗的患者的结局。在2020年3月至2023年2月期间，连续治疗了34例适合的CD33 + AML患者，中位年龄54.5岁（范围25 - 75岁）。本研究证实了临床试验中报告的疗效和毒性数据，突出了基于吉妥珠单抗奥唑米星的化疗在60岁以上患者中的可行性，以及作为异基因造血干细胞移植（allo - HSCT）桥梁的可行性。
